New Fixed‐Dose Combinations of Fenofibrate/Simvastatin Therapy Significantly Improve the Lipid Profile of High‐Risk Patients with Mixed Dyslipidemia Versus Monotherapies

By  

CARDIOVASCULAR THERAPEUTICS (ELECTRONIC), Vol. 33, Iss. 6, 2015-12 ,pp. : 329-337

John Wiley & Sons Inc

Access to resources Recommend Favorite

Prediction of cardiovascular event risk reduction from lipid changes associated with high potency dyslipidemia therapy

By Charland Scott L.   Malone Daniel C.  

Current Medical Research and Opinion, Vol. 26, Iss. 2, 2010-02 ,pp. : 365-375

Informa Healthcare

Access to resources Recommend Favorite

Evaluating optimal lipid levels in patients with mixed dyslipidemia following short- and long-term treatment with fenofibric acid and statin combination therapy: a post hoc analysis

By Mohiuddin Syed M.   Thakker Kamlesh M.   Setze Carolyn M.   Kelly Maureen T.  

Current Medical Research and Opinion, Vol. 27, Iss. 5, 2011-05 ,pp. : 1067-1078

Informa Healthcare

Access to resources Recommend Favorite

Adherence to single-pill combination versus multiple-pill combination lipid-modifying therapy among patients with mixed dyslipidemia in a managed care population

By Kamat Siddhesh A.   Bullano Michael F.   Chang Chun-Lan   Gandhi Sanjay K.   Cziraky Mark J.  

Current Medical Research and Opinion, Vol. 27, Iss. 5, 2011-05 ,pp. : 961-968

Informa Healthcare

Access to resources Recommend Favorite

Effects of ezetimibe added to on-going statin therapy on the lipid profile of hypercholesterolemic patients with diabetes mellitus or metabolic syndrome

By Simons Leon   Tonkon Melvin   Masana Luis   Maccubbin Darbie   Shah Arvind   Lee Michael   Gumbiner Barry  

Current Medical Research and Opinion, Vol. 20, Iss. 9, 2004-09 ,pp. : 1437-1445

Informa Healthcare

Access to resources Recommend Favorite